GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042059 describes any process that stops, prevents, or reduces the frequency, rate, or extent of epidermal growth factor receptor (EGFR) signaling pathway activity.
• Negative regulation of EGFR signaling is essential for normal development and tissue homeostasis, and its disruption contributes to cancer and other diseases [3,4].
• Key negative regulators include inducible feedback inhibitors such as LRIG1, RALT/MIG6, and SOCS proteins, which attenuate EGFR signaling through multiple mechanisms.
• EGFR signaling is also negatively regulated by heterologous pathways, including growth hormone (GH) signaling, which attenuates EGF-induced responses.
• Dysregulation of negative regulation of EGFR signaling is implicated in non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, and gastric cancer [1,2,5].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulators of EGFR signaling in disease contexts [1,4].
Description
The epidermal growth factor receptor (EGFR) signaling pathway is a highly conserved cascade that controls cell proliferation, survival, differentiation, and migration [4,6]. To prevent excessive or inappropriate signaling, cells employ multiple layers of negative regulation that collectively constitute the Gene Ontology biological process GO:0042059, negative regulation of epidermal growth factor receptor signaling pathway. This process encompasses any mechanism that stops, prevents, or reduces the frequency, rate, or extent of EGFR signaling activity. Understanding these negative regulatory mechanisms is critical because their failure can lead to uncontrolled cell growth and cancer [3,4]. Negative regulation of EGFR signaling operates at multiple levels, including ligand sequestration, receptor downregulation, and intracellular feedback inhibition. Inducible feedback inhibitors such as LRIG1, RALT/MIG6, and SOCS family proteins are rapidly induced upon EGFR activation and act to dampen the signal. Additionally, heterologous pathways such as growth hormone signaling can attenuate EGF-induced responses, demonstrating crosstalk between negative regulatory networks. In Drosophila, negative regulators of EGFR signaling are essential for proper development, highlighting the evolutionary conservation of this process. For researchers, GO:0042059 provides a framework to study how cells maintain signaling homeostasis and how disruption of these brakes contributes to diseases such as non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, and gastric cancer [1,2,5]. Experimental models that manipulate negative regulators, including CRISPR knockout and knock-in, are powerful tools to dissect these mechanisms and identify therapeutic targets [1,4].
negative regulation of epidermal growth factor receptor signaling pathway At A Glance
| GO ID | GO:0042059 |
|---|---|
| GO term | negative regulation of epidermal growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of epidermal growth factor receptor signaling pathway; down-regulation of epidermal growth factor receptor signaling pathway; downregulation of epidermal growth factor receptor signaling pathway; inhibition of epidermal growth factor receptor signaling pathway; negative regulation of EGF receptor signaling pathway; negative regulation of EGF receptor signalling pathway; negative regulation of EGFR signaling pathway |
| Major function | Attenuation or suppression of EGFR-mediated signal transduction to maintain cellular homeostasis. |
| Key regulators | Inducible feedback inhibitors (e.g., LRIG1, RALT/MIG6, SOCS proteins), receptor trafficking components, and heterologous pathways such as growth hormone signaling [3,8]. |
| Associated diseases | Non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, gastric cancer [1,2,5]. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, imaging, and biochemical assays [1,4]. |
What Is GO:0042059?
GO:0042059, negative regulation of epidermal growth factor receptor signaling pathway, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of epidermal growth factor receptor signaling pathway activity. This biological process includes mechanisms such as receptor internalization and degradation, induction of feedback inhibitors, and crosstalk from other signaling pathways that suppress EGFR-mediated signals [3,8].
Why Is negative regulation of epidermal growth factor receptor signaling pathway Important in Cell Biology?
Negative regulation of EGFR signaling is crucial for preventing aberrant cell proliferation and maintaining tissue homeostasis. Dysregulation of this process is a hallmark of many cancers, where loss of negative regulators leads to sustained EGFR activation and tumor progression [3,4]. Understanding GO:0042059 provides insights into fundamental cell signaling mechanisms and identifies potential therapeutic targets for cancer and other diseases [1,5].
• Prevents excessive EGFR signaling that could lead to uncontrolled cell growth.
• Essential for normal embryonic development and organogenesis, as shown in Drosophila models.
• Loss of negative regulators such as LRIG1 or RALT/MIG6 is associated with various cancers.
• Provides targets for therapeutic intervention in EGFR-driven cancers, including non-small cell lung cancer and triple-negative breast cancer.
• Crosstalk with growth hormone signaling demonstrates integration of negative regulatory networks.
• Involved in colorectal cancer progression through regulation of Cten and other effectors.
• Relevant to gastric cancer biology via HER2/ErbB2 signaling, a related EGFR family member.
• Guides development of combination therapies that target both EGFR and its negative regulators.
• Offers a paradigm for understanding feedback inhibition in other receptor tyrosine kinase pathways.
• Enables precision medicine approaches by stratifying tumors based on negative regulator status.
What Happens During negative regulation of epidermal growth factor receptor signaling pathway?
Ligand sequestration and receptor downregulation
In simple terms: Cells reduce the amount of signal by removing receptors from the surface or blocking ligands.
Negative regulation of EGFR signaling can occur through ligand sequestration or receptor internalization and degradation. Inducible feedback inhibitors such as LRIG1 enhance receptor ubiquitination and degradation, thereby reducing the number of active receptors on the cell surface. This process ensures that signaling is transient and prevents sustained activation.
Inducible feedback inhibitors
In simple terms: When EGFR is active, it turns on genes that later shut the signal down.
A key mechanism of negative regulation involves the rapid induction of feedback inhibitors such as RALT/MIG6, LRIG1, and SOCS proteins upon EGFR activation. These proteins act at multiple nodes to attenuate the signal, including inhibition of receptor phosphorylation, promotion of receptor degradation, and interference with downstream effectors. This negative feedback loop is essential for maintaining signaling fidelity.
Crosstalk with heterologous pathways
In simple terms: Other signaling pathways can put the brakes on EGFR signaling.
Negative regulation of EGFR signaling can also be mediated by heterologous pathways. For example, growth hormone (GH) signaling attenuates EGF-induced responses, demonstrating that crosstalk between pathways can suppress EGFR activity. This integration allows cells to coordinate responses to multiple environmental cues.
Regulation of downstream effectors
In simple terms: Even after EGFR is active, its downstream messengers can be blocked.
Negative regulation can occur at the level of downstream effectors. For instance, proteins such as Cten are regulated by multiple pathways in colorectal cancer, and their modulation can impact EGFR signaling output. Additionally, in Drosophila, negative regulators of EGFR signaling control developmental processes by modulating the activity of downstream transcription factors.
Key Genes Involved in GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
The following genes and proteins are key players in the negative regulation of EGFR signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LRIG1 | Inducible feedback inhibitor; promotes EGFR degradation | Frequently downregulated in cancers; target for CRISPR knockout studies |
| RALT/MIG6 | Feedback inhibitor; binds to EGFR and inhibits signaling | Loss associated with tumor progression; used in overexpression models |
| SOCS1 | Suppresses EGFR signaling via ubiquitination | Implicated in cancer and inflammation; knockout models available |
| SOCS3 | Negative regulator of EGFR and other cytokine receptors | Studied in cancer and metabolic diseases |
| CBL | E3 ubiquitin ligase; mediates EGFR ubiquitination and degradation | Key for receptor downregulation; knockout affects signaling |
| GH | Growth hormone; attenuates EGF signaling | Crosstalk studies; knockout and transgenic models |
| EGFR | Receptor tyrosine kinase; target of negative regulation | Central to pathway; mutations in cancer |
| ERBB2 | Heterodimerization partner; modulated by negative regulators | Relevant to gastric and breast cancer |
| Cten | Regulated by multiple pathways; affects EGFR signaling | Colorectal cancer research; knockout models |
| SPRY2 | Feedback inhibitor of EGFR signaling | Developmental and cancer studies |
| SPRED1 | Negative regulator of Ras-MAPK pathway downstream of EGFR | Neurofibromatosis and cancer research |
| D-Cbl | Drosophila homolog of CBL; regulates EGFR degradation | Developmental studies in Drosophila |
| Argos | Drosophila ligand antagonist; inhibits EGFR signaling | Developmental patterning; genetic screens |
| Kekkon1 | Drosophila negative regulator of EGFR | Developmental studies |
| Mebendazole | Small molecule that disrupts EGFR signaling | Used in combination with gefitinib in cancer cell lines |
| Gefitinib | EGFR tyrosine kinase inhibitor | Used to study negative regulation in NSCLC and TNBC |
How Is negative regulation of epidermal growth factor receptor signaling pathway Regulated?
The negative regulation of EGFR signaling is itself tightly regulated. Inducible feedback inhibitors are transcriptionally upregulated upon EGFR activation, creating a negative feedback loop. Additionally, post-translational modifications such as ubiquitination and phosphorylation control the stability and activity of negative regulators. Crosstalk with pathways such as growth hormone signaling can modulate the strength of negative regulation. In Drosophila, multiple negative regulators are deployed in a stage- and tissue-specific manner to shape developmental outcomes.
negative regulation of epidermal growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LRIG1 | Cancer (various), loss promotes tumor growth | CRISPR knockout in cancer cell lines |
| RALT/MIG6 | Cancer, loss associated with poor prognosis | Overexpression and knockout models |
| Cten | Colorectal cancer | Knockout and knock-in in colorectal cancer cells |
| EGFR | Non-small cell lung cancer, triple-negative breast cancer | Point mutation (e.g., T790M) and knockout [1,4] |
| ERBB2 | Gastric cancer | Knock-in of HER2 mutations; overexpression |
Cancer
Dysregulation of negative regulation of EGFR signaling is a common feature of many cancers. Loss of feedback inhibitors such as LRIG1 or RALT/MIG6 leads to sustained EGFR activation, promoting tumor growth and survival. In non-small cell lung cancer and triple-negative breast cancer, disruption of EGFR signaling by compounds like mebendazole and gefitinib can synergistically impair paracrine cytokine signaling. Colorectal cancer progression involves altered regulation of Cten, which is controlled by multiple pathways and impacts EGFR signaling. Gastric cancer often involves HER2 (ERBB2) signaling, a close relative of EGFR, and its negative regulation is critical for therapeutic response.
Developmental disorders
In Drosophila, negative regulators of EGFR signaling are essential for proper development; mutations in these regulators cause developmental defects. This highlights the evolutionary importance of negative regulation in tissue patterning and organogenesis.
Metabolic and endocrine crosstalk
Growth hormone signaling negatively regulates EGF signaling, linking endocrine status to EGFR activity. This crosstalk may be relevant in conditions where growth hormone levels are altered, such as acromegaly or growth disorders.
From negative regulation of epidermal growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LRIG1 enhance EGFR signaling? | CRISPR knockout of LRIG1 in cell lines |
| Does a specific point mutation in EGFR affect negative regulation? | CRISPR point mutation knock-in |
| Can overexpression of RALT/MIG6 suppress tumor growth? | CRISPR-mediated overexpression |
| How does GH signaling attenuate EGF responses? | Knockout of GH receptor or GH itself |
| What is the role of Cten in colorectal cancer? | Knockout and tagged knock-in of Cten |
| Does mebendazole synergize with gefitinib to disrupt EGFR signaling? | Cell line models with CRISPR knockout of EGFR |
How to Study the negative regulation of epidermal growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on EGFR signaling | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Measure pathway output after knockout |
| Phosphoproteomics | Phosphorylation status of signaling proteins | Quantify EGFR activity |
| Immunoblotting | Protein levels and phosphorylation | Validate specific regulators |
| Immunofluorescence | Subcellular localization of EGFR | Study receptor trafficking |
| Co-immunoprecipitation | Protein-protein interactions | Identify complexes with negative regulators |
| Luciferase reporter assays | Transcriptional activity of EGFR targets | Measure pathway activity |
| Cell proliferation assays | Growth rate | Assess functional impact of negative regulators |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify negative regulators of EGFR signaling. Cells are transduced with a library of guide RNAs, and those with enhanced EGFR signaling are selected, revealing candidate genes whose loss increases pathway activity [1,4].
RNA-seq and transcriptomics
RNA sequencing can measure changes in gene expression upon manipulation of negative regulators. For example, knockout of LRIG1 may lead to upregulation of EGFR target genes, which can be quantified by RNA-seq.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can assess changes in protein abundance and phosphorylation status of EGFR and downstream effectors upon modulation of negative regulators.
Imaging and biochemical assays
Fluorescence microscopy can visualize receptor internalization and degradation, while immunoblotting can quantify phosphorylation levels of EGFR and its targets [3,8].
How CRISPR Can Be Used to Study GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
Knockout
CRISPR knockout of negative regulators such as LRIG1, RALT/MIG6, or SOCS proteins can be used to study their role in EGFR signaling. Loss of these genes typically enhances and prolongs EGFR signaling, providing a direct test of their function.
Point Mutation
Point mutations can be introduced into EGFR or its negative regulators to model cancer-associated mutations. For example, the EGFR T790M mutation reduces sensitivity to gefitinib and may alter negative regulation.
Knock-in
Knock-in of tagged versions of negative regulators (e.g., GFP-LRIG1) allows real-time tracking of protein localization and dynamics. This can reveal how these proteins interact with EGFR at the single-cell level.
Overexpression
CRISPR-mediated overexpression of negative regulators such as RALT/MIG6 can suppress EGFR signaling and inhibit tumor growth, offering a potential therapeutic strategy.
How EDITGENE Supports negative regulation of epidermal growth factor receptor signaling pathway Research
Researchers studying negative regulation of epidermal growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in attenuating EGFR signaling or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of these regulators.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of epidermal growth factor receptor signaling pathway research.
Frequently Asked Questions About negative regulation of epidermal growth factor receptor signaling pathway
What is GO:0042059?
GO:0042059 is the Gene Ontology term for negative regulation of epidermal growth factor receptor signaling pathway, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of EGFR signaling activity.
What genes are involved in negative regulation of EGFR signaling?
Key genes include LRIG1, RALT/MIG6, SOCS1, SOCS3, CBL, and SPRY2, among others [3,7].
How does negative regulation of EGFR signaling occur?
It occurs through mechanisms such as receptor downregulation, inducible feedback inhibitors, and crosstalk with heterologous pathways like growth hormone signaling [3,8].
Why is negative regulation of EGFR signaling important in cancer?
Loss of negative regulation leads to sustained EGFR activation, which promotes tumor growth and survival in cancers such as non-small cell lung cancer and triple-negative breast cancer [1,3].
What diseases are associated with defective negative regulation of EGFR signaling?
Cancers including non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, and gastric cancer, as well as developmental disorders [1,2,5,7].
How can CRISPR be used to study negative regulation of EGFR signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of negative regulators to assess their impact on EGFR signaling [1,4].
What are inducible feedback inhibitors of EGFR?
Inducible feedback inhibitors are proteins such as LRIG1, RALT/MIG6, and SOCS that are upregulated upon EGFR activation and act to dampen the signal.
Does growth hormone affect EGFR signaling?
Yes, growth hormone signaling can attenuate EGF-induced responses, demonstrating crosstalk between pathways.
What model organisms are used to study negative regulation of EGFR signaling?
Drosophila melanogaster is a key model, where negative regulators control developmental processes. Mammalian cell lines are also widely used [1,3].
How can I create a knockout of a negative regulator of EGFR signaling?
EDITGENE provides custom CRISPR knockout services for genes such as LRIG1, RALT/MIG6, and SOCS1, with validated cell lines and functional characterization.
Conclusion
Negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059) is a fundamental biological process that prevents excessive EGFR signaling and maintains cellular homeostasis. Its dysregulation is implicated in multiple cancers and developmental disorders, making it a critical area of research [1,2,5,7]. Advances in CRISPR-based models and bioinformatics are enabling precise dissection of these regulatory mechanisms, offering new opportunities for therapeutic intervention [1,4]. EDITGENE supports this research with comprehensive gene editing and screening services.
References
- 1. El-Tanani M et al.. 2025. Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines.. PLoS One 20(12):e0338027 PMID: 41401147
- 2. Thorpe H et al.. 2015. Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.. Int J Exp Pathol 96(6):362-9 PMID: 26852686
- 3. Segatto O et al.. 2011. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors.. J Cell Sci 124(Pt 11):1785-93 PMID: 21576352
- 4. Wang Z. 2017. ErbB Receptors and Cancer.. Methods Mol Biol 1652:3-35 PMID: 28791631
- 5. Jørgensen JT. 2014. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.. World J Gastroenterol 20(16):4526-35 PMID: 24782605
- 6. Merlino GT. 1990. Epidermal growth factor receptor regulation and function.. Semin Cancer Biol 1(4):277-84 PMID: 2103502
- 7. Shilo BZ. 2003. Signaling by the Drosophila epidermal growth factor receptor pathway during development.. Exp Cell Res 284(1):140-9 PMID: 12648473
- 8. González L et al.. 2017. Attenuation of epidermal growth factor (EGF) signaling by growth hormone (GH).. J Endocrinol 233(2):175-186 PMID: 28223314
